Comparison of prednisolone, vincristine, methotrexate and 6‐mercaptopurine vs. 6‐mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: A southwest oncology group study

D. H. Berry, D. J. Fernbach, J. Herson, J. Pullen, M. P. Sullivan, T. J. Vietti

Research output: Contribution to journalArticle

Abstract

The study was designed to compare the relapse rate and toxicity of intermittent prednisone, oncovin (vincristine), methotrexate, and 6‐mercaptopurine (POMP) vs. 6‐mercaptopurine daily and a prednisone pulse every three months (PIP) for maintenance therapy in acute leukemia. Children with acute lymphoblastic, acute undifferentiated, or acute stem‐cell leukemia were stratified on the basis of initial leukocyte count and age, then randomly assigned to POMP or PIP maintenance therapy. All patients received cranial irradiation and intrathecal chemotherapy. Of the 67 patients receiving POMP maintenance, 20 (30%) remain in continuous remission. The median length of continuous remission achieved with POMP therapy was 49 weeks. Of 80 patients receiving PIP maintenance, 25 (31%) remain in remission. The median length of continuous remission for PIP was 62 weeks. Of the possible prognostic factors evaluated, the only significant factor was the prognostic grouping base in age and initial leukocyte count. Prognostic group I contained the patients with the longest duration of remission. The POMP regimen was associated with a higher incidence of toxic reactions, frequently causing therapy interruption. The results for both regimens as studied are inferior to those for 6‐mercaptopurine‐methotrexate maintenance regimens as reported by others.

Original languageEnglish (US)
Pages (from-to)1098-1103
Number of pages6
JournalCancer
Volume46
Issue number5
DOIs
StatePublished - Sep 1 1980
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this